Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Bone Biologics Zack’s Small Cap Research Issues Note With $8 Valuation Target On Stock

https://s27.q4cdn.com/906368049/files/News/2022/Zacks_SCR_Research_03182022_BBLG_Sorensen.pdf

byBenzinga Newsdesk

March 18, 2022

1 minute read

https://s27.q4cdn.com/906368049/files/News/2022/Zacks_SCR_Research_03182022_BBLG_Sorensen.pdf

Truist Securities Maintains Buy on Amedisys, Lowers Price Target to $190

By Benzinga Newsdesk

Today, 4:14 AM

Truist Securities analyst David Macdonald maintains Amedisys (NASDAQ:AMED) with a Buy and lowers the price target from $255 to $190.

AMED

Analyst Ratings

Analyst Ratings for Hims & Hers Health

By Benzinga Insights

Today, 4:14 AM

Within the last quarter, Hims & Hers Health (NYSE:HIMS) has observed the following analyst ratings:

HIMS

Disney’s Combined Strength Across Sectors Remains ‘Unparalleled’ In Global Media Industry, Says Dan Loeb

By Madhukumar Warrier

Today, 4:14 AM

Activist investor Dan Loeb noted that the combined strength of Walt Disney Co.’s (NYSE: DIS) various sports, general entertainment, and blockbuster franchises remains “unparalleled” in the global media industry.

DIS

$10 Million Bet On This Financial Services Stock? 3 Stocks Insiders Are Buying

By Lisa Levin

Today, 4:14 AM

Although US stocks closed mixed on Monday, there were a few notable insider trades.

BKR

Bone Biologics Zack’s Small Cap Research Issues Note With $8 Valuation Target On Stock

Related Posts

Truist Securities Maintains Buy on Amedisys, Lowers Price Target to $190

Analyst Ratings for Hims & Hers Health

Disney’s Combined Strength Across Sectors Remains ‘Unparalleled’ In Global Media Industry, Says Dan Loeb

$10 Million Bet On This Financial Services Stock? 3 Stocks Insiders Are Buying